Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in Multiple Cancers in India (KEYNOTE-G44)
NCT07801027Phase 4Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Primary completion
- Jan 2030
01
Overview
A Phase 4 trial of pembrolizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, biliary tract carcinoma (BTC), Cervical Cancer (CC), sponsored by Merck & Co.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomabiliary tract carcinoma (BTC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07801027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801027.